Bank of New York Mellon’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-281,667
| Closed | -$14.8M | – | 4429 |
|
|
2026
Q1 | $14.8M | Buy |
281,667
+23,105
| +9% | +$949K | ﹤0.01% | 1698 |
|
|
2025
Q4 | $10.4M | Buy |
258,562
+50,381
| +24% | +$1.16M | ﹤0.01% | 1902 |
|
|
2025
Q3 | $1.56M | Buy |
208,181
+5,967
| +3% | +$38.1K | ﹤0.01% | 2948 |
|
|
2025
Q2 | $754K | Buy |
202,214
+15,301
| +8% | +$47.8K | ﹤0.01% | 3280 |
|
|
2025
Q1 | $516K | Buy |
186,913
+605
| +0.3% | +$2.47K | ﹤0.01% | 3416 |
|
|
2024
Q4 | $1.03M | Buy |
186,308
+24,930
| +15% | +$169K | ﹤0.01% | 3144 |
|
|
2024
Q3 | $1.35M | Sell |
161,378
-15,295
| -9% | -$126K | ﹤0.01% | 2970 |
|
|
2024
Q2 | $1.2M | Buy |
176,673
+64,018
| +57% | +$388K | ﹤0.01% | 3088 |
|
|
2024
Q1 | $739K | Sell |
112,655
-7,430
| -6% | -$48.5K | ﹤0.01% | 3311 |
|
|
2023
Q4 | $779K | Sell |
120,085
-8,939
| -7% | -$47.3K | ﹤0.01% | 3321 |
|
|
2023
Q3 | $649K | Buy |
129,024
+646
| +0.5% | +$4.1K | ﹤0.01% | 3412 |
|
|
2023
Q2 | $1.12M | Buy |
128,378
+107,990
| +530% | +$1.26M | ﹤0.01% | 3129 |
|
|
2023
Q1 | $241K | Buy |
+20,388
| New | +$195K | ﹤0.01% | 3847 |
|
|
2022
Q2 | – | Sell |
-38,059
| Closed | -$112K | – | 4696 |
|
|
2022
Q1 | $112K | Buy |
38,059
+2,359
| +7% | +$10.1K | ﹤0.01% | 4386 |
|
|
2021
Q4 | $253K | Buy |
35,700
+8,187
| +30% | +$68.2K | ﹤0.01% | 4167 |
|
|
2021
Q3 | $287K | Buy |
27,513
+4,227
| +18% | +$43.9K | ﹤0.01% | 4059 |
|
|
2021
Q2 | $286K | Buy |
23,286
+4,007
| +21% | +$68.3K | ﹤0.01% | 3983 |
|
|
2021
Q1 | $424K | Buy |
+19,279
| New | +$423K | ﹤0.01% | 3778 |
|
Other funds holding TERN
Bank of New York Mellon's TERN Position: Q2 2026 in Review
Bank of New York Mellon sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 281,667 shares — an estimated $14.8M sold.
Bank of New York Mellon first reported a position in TERN in Q1 2021 and held it in 18 quarters. The position peaked at $14.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Bank of New York Mellon reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Bank of New York Mellon sold 281,667 Terns Pharmaceuticals shares in Q2 2026, an estimated $14.8M.
- Bank of New York Mellon first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 18 quarters.
- Bank of New York Mellon's Terns Pharmaceuticals position peaked at $14.8M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.